- Switzerland
- /
- Food and Staples Retail
- /
- SWX:DOCM
Some Zur Rose Group AG (VTX:ROSE) Analysts Just Made A Major Cut To Next Year's Estimates
One thing we could say about the analysts on Zur Rose Group AG (VTX:ROSE) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.
After the downgrade, the eight analysts covering Zur Rose Group are now predicting revenues of CHF1.7b in 2021. If met, this would reflect a huge 22% improvement in sales compared to the last 12 months. Per-share losses are expected to creep up to CHF10.38. Yet prior to the latest estimates, the analysts had been forecasting revenues of CHF2.0b and losses of CHF7.03 per share in 2021. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.
Check out our latest analysis for Zur Rose Group
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Zur Rose Group's past performance and to peers in the same industry. It's clear from the latest estimates that Zur Rose Group's rate of growth is expected to accelerate meaningfully, with the forecast 22% annualised revenue growth to the end of 2021 noticeably faster than its historical growth of 8.9% over the past year. Compare this with other companies in the same industry, which are forecast to grow their revenue 3.6% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Zur Rose Group to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that analysts increased their loss per share estimates for this year. While analysts did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market. Given the serious cut to this year's outlook, it's clear that analysts have turned more bearish on Zur Rose Group, and we wouldn't blame shareholders for feeling a little more cautious themselves.
Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple Zur Rose Group analysts - going out to 2025, and you can see them free on our platform here.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
If you’re looking to trade Zur Rose Group, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About SWX:DOCM
DocMorris
Operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally.
Fair value with mediocre balance sheet.